Q1: 2026-05-13 Earnings Summary
EPS of -$0.18 beats by $0.07
| Revenue of $0.00 misses by $1,110.00
Altimmune, Inc. (ALT) Q1 2026 Earnings Call May 13, 2026 8:30 AM EDT
Company Participants
Luis Sanay
Jerome Durso – Chairman, CEO & President
Christophe Arbet-Engels – Chief Medical Officer
Linda Richardson – Chief Commercial Officer
Gregory Weaver – Chief Financial Officer
Conference Call Participants
Eliana Merle – Barclays Bank PLC, Research Division
Jiale Song – Jefferies LLC, Research Division
Annabel Samimy – Stifel, Nicolaus & Company, Incorporated, Research Division
Michael DiFiore – Evercore ISI Institutional Equities, Research Division
Srikripa Devarakonda – Truist Securities, Inc., Research Division
William Wood – B. Riley Securities, Inc., Research Division
Anupam Damani – Goldman Sachs Asset Management, L.P.
Jonathan Wolleben – Citizens JMP Securities, LLC, Research Division
Tsan-Yu Hsieh – William Blair & Company L.L.C., Research Division
Presentation
Operator
Good morning, ladies and gentlemen, and welcome to the Altimmune First Quarter 2026 Financial Results Conference Call. [Operator Instructions] As a reminder, this call is being recorded. I’ll now introduce your host for today’s conference call, Luis Sanay, Vice President of Investor Relations. Luis, you may begin.
Luis Sanay
Thank you, operator, and good morning, everyone. Thank you for joining us for Altimmune’s First Quarter 2026 Financial Results and Business Update Call.
On today’s call, you will hear from Jerry Durso, our President and Chief Executive Officer; Dr. Christophe Arbet-Engels, Chief Medical Officer; Linda Richardson, Chief Commercial Officer; and Greg Weaver, Chief Financial Officer. Following management’s prepared remarks, we’ll open the line for the Q&A session. Our first quarter 2026 earnings release was issued this morning and can be found on the Investor Relations section of our website.
Before we begin, I would like to remind everyone that remarks made about future expectations, plans and prospects constitute forward-looking statements for purposes of safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Altimmune cautions that these forward-looking statements are subject to risks and uncertainties that
